MPR

A late-stage study of fianlimab and cemiplimab as first-line therapy for unresectable or metastatic melanoma missed its primary efficacy endpoint. empr.com/news/fianlimab…

Amazon customers may have received expired emergency contraception. Several lots of expired levonorgestrel were delivered between January and April. empr.com/news/fda-warns…

High-risk of cross-border spread for current ebola outbreak, declares WHO. The US withdrew from WHO under the Trump administration earlier this year. empr.com/news/ebola-out…

New hypertension treatment Baxfendy inhibits aldosterone synthase resulting in decreased plasma aldosterone and a subsequent reduction in blood pressure. empr.com/news/baxfendy-…

Tecentriq becomes the first immunotherapy approved for a ctDNA-guided adjuvant indication in muscle-invasive bladder cancer. #DrugApprovals empr.com/news/fda-appro…

New #Crysvita dosing guidance for adults with XLH who experience serum phosphorus levels below the normal range after the initial treatment period. empr.com/news/crysvita-…

🎧 New Weekly Dose Pod out now! 🏪US News release their annual best OTC products; 🤰Drug safety evaluation during pregnancy; 🔹gMG indication broadened for efgartigimod; 🔸Beqalzi gains accelerated approval for MCL; & 🧠Novel Tx fast tracked for ALS. empr.com/news/mpr-weekl…

Makary out at the FDA. Kyle Diamantas, the FDA's top food regulator, will step in as acting commissioner. empr.com/news/fda-commi…

Transitioning to a lower dose of GLP-1 shows maintained weight loss in two new trials. empr.com/news/weight-lo…

Fake references used in medical papers is on the rise; one in 277 papers in the first months of 2026 had a fabricated reference. empr.com/news/audit-stu…

Relapsing MS drug gains expanded approval to treat children with the disease. empr.com/news/ocrevus-f…

The top over-the-counter treatments across 128 categories were ranked by US clinicians in a comprehensive survey. Find out what topped the lists. empr.com/news/top-otc-p…

🎧 New MPR Pod out now! This week: 💊 Ozempic tablets now available; 🧠 Potential ALS treatment Fast Tracked; ❤️ Aficamten for non-obstructive HCP; 🚢 Motion sickness drug Nereus now available; and 🔸 Lantus interchangeable give FDA nod. #MPRPod #Podcast empr.com/news/mpr-weekl…

An outbreak on a cruise ship has highlighted the dangers of hantavirus; what does diagnosis and management entail? #Hantavirus empr.com/news/cruise-sh…

Tazbentetol demonstrated a stable or improved rate of decline in 82% of the treated ALS patients, in a phase 2a trial. empr.com/news/fda-grant…

The pause, allowing patients continued access to the abortion pill, will last until at least May 11, when the full court will then determine how to move forward. #Mifepristone empr.com/news/supreme-c…

Novel motion sickness treatment, Nereus, now available for adults. empr.com/news/motion-si…

📢 This week's top pharma news in 10 minutes, its the latest MPR Weekly Dose! 👂 First gene therapy for hearing loss; 👴 Male pattern hair loss treatment; 🫁 Breztri approved as asthma treatment; and 🔹 Novel GLP-1 demonstrates significant weight loss. empr.com/news/mpr-weekl…

Effective May 4, 2026, oral semaglutide will be available as Ozempic tablets in 1.5mg, 4mg, and 9mg strengths. #Ozempic #GLP1 empr.com/news/ozempic-s…

Boehringer Ingelheim's novel glucagon/GLP-1 obesity treatment shows efficacy in phase 3 trial. #DrugsInThePipeline empr.com/news/survoduti…